Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
iCAD Exhibiting New Updates and Enhanced Xoft Platform at ASTRO Including Single-Fraction IORT Solution for the Treatment of Early-Stage Breast Cancer | ||
By: Nasdaq / GlobeNewswire - 16 Sep 2019 | Back to overview list |
|
Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers NASHUA, N.H. and CHICAGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase its latest advancements for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, including new and updated x-ray sources and the full suite of applicators for existing and emerging applications in the Xoft exhibition booth (#4205) at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Chicago at McCormick Place West from September 15-18, 2019. iCAD will also be concurrently exhibiting at the Society for Radiation Oncology Administrators (SROA) Annual Meeting at the Hilton Chicago from September 15-18, 2019. “The Xoft System is a transformative radiation treatment option that offers a targeted, single-fraction therapy for early-stage breast cancer, along with the added versatility and cross-functionality to treat other types of cancers, such as nonmelanoma skin cancers and gynecological cancers,” according to Gary Proulx, MD, medical director and radiation oncologist at Exeter Hospital and featured expert speaker at iCAD’s “Evening of eBx” event scheduled to take place during the meeting. “As cancer treatment becomes increasingly targeted and value-based, iCAD’s Xoft System continues to be an established trailblazer in this revolutionary trend towards more personalized cancer treatment.” Leading experts will be available in the Xoft booth throughout ASTRO and SROA to discuss their clinical experience using the technology across various cancer types. The Xoft System will be available for demonstration in the booth at ASTRO and new and updated advancements will be unveiled, including those highlighted below:
For early-stage breast cancer patients, IORT with the Xoft System allows appropriately selected patients to potentially replace six to eight weeks of post-operative external beam radiation therapy (EBRT) with a single-fraction of radiation that can last as little as eight minutes. It uses a miniaturized x-ray source to deliver one precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body. “We may be approaching a significant paradigm shift in the way clinicians treat cancer, especially with a likely decision on the Radiation Oncology Alternative Payment Model (RO-APM) anticipated in the months ahead,” said Michael Klein, Chairman and CEO of iCAD. “As a single-fraction treatment therapy for early-stage breast cancer, Xoft IORT is a viable and verified treatment option that appears well-aligned with the core elements of the proposed model. The Company is poised to transform patient experiences and outcomes in the years ahead as a platform technology across multiple cancer indications.” A growing body of evidence continues to support the Xoft System across multiple cancer types. At ASTRO, findings from a Vanderbilt University School of Medicine study supporting Xoft IORT for early-stage breast cancer will be presented on Sunday, September 15 at 1:15 pm CT in the Breast Cancer Track. iCAD will also host “An Evening of eBx” cocktail reception on Monday, September 16, at the Marriott Marquis Chicago at 6 pm CT. The event will feature clinical experts who will discuss the latest research and emerging applications for eBx and IORT with the Xoft System. The Xoft System is FDA-cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, nonmelanoma skin cancer, and gynecological cancers. For more information, please visit www.xoftinc.com. About iCAD, Inc. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Contacts: Media Inquiries: Investor Relations: |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |